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Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder consisting of progres-
sive loss of motor neurons. TDP-43 has been identified as a component of ubiquitin-
immunoreactive inclusions of motor neurons inALS.We focused on the diffuse cytoplasmic
TDP-43 immunoreactivity in ALS neurons, and quantitatively assessed it in comparison
with skein/round TDP-43 and ubiquitin immunostaining in motor neurons of 30 sporadic
ALS cases. The percentage of spinal motor neurons with cytoplasmicTDP-43 immunoreac-
tivity was higher than that of ubiquitin-immunoreactive ones. The percentage of TDP-43-
positive motor neurons was independent of neuron counts in anterior horns, while the
percentage of ubiquitinated neurons was inversely correlated.Aiming to define the cytosolic
localization of TDP-43, the immunoblot analysis of spinal cord and frontal cortex showed
that full-lengthTDP-43, the 45 kDa form and ubiquitinatedTDP-43 are found in the soluble
inclusion-free fraction. The present data suggest that delocalization, accumulation and
ubiquitination of TDP-43 in the cytoplasm of motor neurons are early dysfunctions in the
cascade of the events leading to motor neuron degeneration inALS, preceding the formation
of insoluble inclusion bodies. Being cytoplasmic accumulation an ongoing event during the
course of the illness, a therapeutic approach to this incurable disease can be envisaged.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a progressive degenerative
disorder in which the selective death of motor neurons in the brain
and spinal cord leads to paralysis of voluntary muscles. Most cases
are sporadic; less than 10% are inherited. Although excessive exci-
tatory tone, protein misfolding, alterations in axonal transport, dys-
function of energy production and calcium metabolism have been
described (30), the underlying pathological events of motor neuron
death remain unclear.
The neuropathological hallmark of ALS is the intracytoplasmic
accumulation of ubiquitin-tagged proteins in motor neurons,
appearing as round or skein-like inclusions. Recently, TDP-43 has
been identified as a component of these inclusions in ALS (2, 29,
37), as well as in frontotemporal lobar degeneration (FTLD) with
and without motor neuron disease (7, 9, 29). TDP-43 has been
shown to be a major disease protein in ALS (20), a view strength-
ened by the finding of TDP-43 gene mutations in familial and
sporadic ALS cases (13, 18, 35, 42), and of direct links between
gene mutation and TDP-43 neuropathology in ALS (40). The
mechanisms underlying the segregation of TDP-43 into cytoplas-
mic ubiquitinated aggregates and the implication of TDP-43 in the
pathogenesis of neurodegeneration remain unknown.
TDP-43 and ubiquitin colocalize within the pathological cyto-
plasmic skein/round inclusions (23); however, the spectrum of
TDP-43 immunoreactivity appears to be wider than that of
ubiquitin, and includes diffuse cytoplasmic immunoreactivity and
diffuse punctate cytoplasmic staining in ALS (2, 12, 27, 33, 36)
and in sporadic FTLD with motor neuron disease (4). The distinct
cytopathological profile consisting of a cleared nucleus and diffuse
cytoplasmic TDP-43 immunostaining may represent an early stage
of inclusion formation and has been considered “pre-inclusions”
(4, 7, 11, 12, 27).
A pathological form ofTDP-43 has been found biochemically in
sarkosyl-insoluble fractions from ALS samples seemingly corre-
sponding to the insoluble inclusion bodies (2, 23, 29, 36). The
biochemical features of the diffuse cytoplasmic TDP-43 seen by
immunohistochemistry are so far not known.
The aims of the present study were to assess the quantitative
relation between the two immunohistochemical patterns (diffuse
staining and skein/round inclusion staining) of TDP-43 in ALS,
and to analyze biochemically TDP-43 and its ubiquitination status
in the cytosolic, inclusion-free fraction from ALS samples. In an
effort to correlate immunohistochemistry and disease progression,
the number of immunopositive neurons was evaluated in relation to
the number of neuron counts in anterior horns of ALS.
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MATERIALS AND METHODS
Patients
Thirty patients with sporadic ALS underwent complete autopsy,
including the brain and spinal cord. Nervous tissue was processed
with formalin–paraffin. Specimens of frontal cortex and spinal
cord from three sporadic ALS cases and three neuropathologically
normal individuals matched for age were stored at -80°C for bio-
chemical analysis.
The ALS patients were seen in a motor neuron diseases clinic.
All patients had the diagnosis of definiteALS at death, according to
the revised El Escorial criteria (5). They ranged in age from 41 to
74 years, and the median age was 61 years at death (9 women and
21 men). The duration of illness ranged from 5 to 60 months with a
median duration of 30 months. The site of onset was bulbar in 10
patients and limbs in 20 patients. Two patients had overt dementia
meeting Neary criteria (28) for clinical frontotemporal dementia: a
43-year-old male patient with behavioral and cognitive changes
preceding themotor symptoms by 6 years, and a 40 year-old female
patient with behavioral abnormalities presenting during the
follow-up of her motor symptoms. A detailed neuropsychological
testing for the evaluation of frontal type impairment was not
performed.
Immunohistochemistry
Serial 5 mm thick paraffin sections from the cervical and lumbar
spinal cord, frontal cortex, temporal cortex and hippocampus were
immunostained by amonoclonal antibody to ubiquitin (clone 1510,
Chemicon, Temecula, Calif.; 1:200), a polyclonal antibody to
TDP-43 (ProteinTech Group, Chicago, Ill.; 1:400) and a mono-
clonal anti-GFAP (clone 6F2, Dako, Glostrup, Denmark; 1:100)
The slides were pretreated by microwave to enhance immunore-
activity. The immune reaction was visualized by Strep-ABC
Vectastain® kit (Vector Laboratories, Burlingame, CA, USA) using
diaminobenzidine as the chromogen. In parallel, TDP-43 immun-
ostaining was visualized by EnVision™ + Dual Link System-HRP
(Dako) in order to check and improve accuracy and consistency.
Quantitation of immunolabeling
The number of motor neurons containing ubiquitin-
immunopositive inclusions and TDP-43 immunostaining were
counted in three distinct slides 100 mm apart of lumbar spinal cord
of each patient. Neurons were identified by the presence of nucleus
and/or nucleolus, or by the large GFAP-negative cell body in adja-
cent section. The percentage of immunopositive neurons out of the
total number of motor neurons seen in each slide was recorded.The
percentage of ubiquitin- and TDP-43-positive neurons was also
counted in 200 hippocampal dentate granule neurons in the most
densely labeled areas of the immunopositive cases.
Colocalization
The double immunofluorescence study was performed on selected
sections using a rabbit polyclonal antibody against TDP-43 (1:200)
and a mouse monoclonal antibody against ubiquitin (clone 1510;
1:200). The secondary antibodies were polyclonal rabbit anti-
mouse TRIC (Dako; 1:100) and polyclonal swine anti-rabbit FITC
(Dako; 1:100). Slides were viewed with a Zeiss Axio-Imager
microscope (Zeiss, Göttingen, Germany).
Biochemical analysis
Reagents
TDP-43 polyclonal antibody (BC001487) was from Protein Tech
Group; glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (sc-
25778) polyclonal antibody and secondary antibodies conjugated
to HRP were from Santa-Cruz, Heidelberg, Germany; ubiquitin
polyclonal antibody (U5379) and protease (P8340) and phos-
phatase (P2850) inhibitor cocktails were from Sigma-Aldrich,
Milan, Italy; lamin B1 monoclonal antibody (33-2000) was from
Zymed Laboratories, San Francisco, Calif.; histone H4 antibody
(2592) was from Cell Signaling Technology (CELBIO, Milan,
Italy); polyvinylidene difluoride (PVDF) membranes were from
GE Healthcare, Milan, Italy; and protein molecular markers (161-
0373) and RCDC protein assay kit were from BioRad, Milan, Italy.
All other chemicals were analytical grade from Sigma-Aldrich.
Tissue fractionation
Frozen specimens of the spinal cord and frontal cortex were
homogenized in isotonic medium, hereafter defined as low salt
buffer (LS-B), consisting of 20 mM Tris (pH 7.2), 5 mM EDTA,
10% sucrose, 1 mL/mL of protease inhibitor cocktail and 2 mL/mL
of phosphatase inhibitor cocktail. The homogenate was centrifuged
at low speed (1.300 ¥ g) for 20 minutes at 4°C, a speed sufficient to
prevent nuclear lysis and to give rise to a supernatant and a pellet
(pellet A) referred to include intact nuclei, unbroken cells and
cellular debris (25, 38). Pellet A was washed in LS-B and pelleted
again at low speed. The supernatant was centrifuged at high speed
(100.000 ¥ g) for 120 minutes at 4°C and resolved in an additional
pellet (pellet B) and in a clear soluble fraction. Pellet B was washed
in LS-B and sedimented again at high speed. The soluble fraction
was centrifuged again at high speed for 60 minutes without no
additional pellet; on this basis, this fraction was defined cytosolic
fraction free from insoluble material (CS-F).
Pellets A and B were separately suspended in a high salt buffer
(HS buffer) consisting of 10 mMTris–HCl (pH 7.5), 1 mM EGTA,
10% sucrose, 0.8 M NaCl, 1 mL/mL of protease inhibitor cocktail
and 2 mL/mL of phosphatase inhibitor cocktail, added to an equal
volume of 2%Triton X-100 in HS buffer.Aliquots of the suspended
pellets A and B were characterized byWestern immunoblotting by
using antibodies to the nuclear envelope marker lamin B1 and the
nuclear matrix or nucleoplasm marker histone H4. The analysis
revealed a strong immunopositivity of both pellets for the two
markers (Figure 1). For this reason, pelletsA and B were combined
and processed by sequential fractionations (15, 16), finally giving
rise to a sarkosyl-insoluble pellet (SarkI-P).
The soluble fraction CS-F was characterized by Western immu-
noblotting by using lamin B1, histone H4 and the cytoplasmic
marker GAPDH.
At the end of these procedures, the soluble fraction (CS-F) and
the SarkI-P were separately added with the urea buffer A, consist-
ing of 50 mM Tris (pH 6.8), 5% (w/v) SDS, 4 M deionized urea,
2% (v/v) b-mercaptoethanol (39), incubated for 30 minutes at
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room temperature, centrifuged at 18 000 ¥ g for 30 minutes, ali-
quoted and finally stored frozen at -70°C. Before freezing, all
preparations were evaluated for protein content using the RC DC
protein assay kit.
Western immunoblotting
Frozen samples of CS-F and SarkI-P were added with urea buffer B
consisting of 50 mM Tris (pH 6.8), 2% glycerol, 5% (w/v) SDS,
4 M deionized urea, 40 mM dithiothreitol, 0.05% (w/v) bromophe-
nol blue (39), incubated for 2 h at room temperature, centrifuged at
18 000 ¥ g for 10 minutes and then subjected to SDS–PAGE on
10% or 12% (w/v) polyacrylamide gels and electroblotted on
PVDF membranes (3). Blotted proteins were immunostained with
antibodies to TDP-43 and ubiquitin. As a control for equal protein
loading, the antibody to GAPDHwas used. Blots are representative
of three or more independent experiments.
RESULTS
Immunohistochemistry
Spinal cord
No immunostaining for ubiquitin was observed in motor neurons
of control cases, while a granular nuclear staining for TDP-43
was present. Skein-like or round intracytoplasmic ubiquitin- and
TDP43-immunoreactive deposits were found in motor neurons of
ALS spinal cords. (Figure 2A,B). Other motor neurons showed
a diffuse TDP-43 immunostaining instead of the skein/round
cytoplasmic aggregates (Figure 2C,D,E,G,H,I); the diffuse pattern
of TDP-43 did not overlap with ubiquitin immunoreactivity
(Figure 2E,F). Diffuse cytoplasmic TDP-43 was found also in
motor neurons of large size and endowed with Nissl substance
(Figure 2H). The nuclei of the neurons with cytoplasmic TDP-43
immunostaining were negative for TDP-43. Rare TDP-43-positive
glial inclusions were present in the anterior horns.
Double immunostaining showed an incomplete overlap of ubiq-
uitin and TDP-43 in some skein/round bodies, with some TDP-43-
positive deposits partially overlapping with ubiquitin-positive ones
(Figure 3A–C).
Hippocampus, frontal cortex, temporal cortex
Cytoplasmic ubiquitin and TDP-43 staining of hippocampal
dentate neurons was found in six ALS patients, including the two
ALS patients with dementia. Nuclear TDP-43 staining was absent
in the dentate neurons with cytoplasmic TDP-43 staining.
In the remaining 24 cases, neither ubiquitin nor cytoplasmic
TDP-43 staining was observed in dentate neurons, while the
nuclear immunoreactivity to the TDP-43 antibody was a constant
finding.
In the temporal and frontal cortex, TDP-43 antibody decorated
the neuronal nuclei; cytoplasmic immunostaining was observed in
neurons of the frontal cortex in oneALS case only (Figure 2J,K).
Quantitative evaluation of immunostaining
Counting of TDP-43-positive neurons was performed in the slides
revealed by the EnVision–Dual Link system which resulted to give
the most consistent results. The mean number and percentage of
TDP-43- and ubiquitin-positive motor neurons in the three slides of
lumbar anterior horns and in the dentate gyrus of the hippocampus,
as well as the mean number of motor neurons counted in the three
slides of lumbar spinal cord, are reported in Table 1.
The overall percentage ofTDP-43-positive spinal motor neurons
ranged from 8% to 94.83% (mean SD: 43.27 23.91). The
overall percentage of spinal motor neurons with TDP-43-positive
skeins or round bodies was 0% to 37.5% (mean SD: 12.17
11.08), and 0% to 88.89% (mean SD: 31.11 27.93) of
neurons had diffuse cytoplasmic immunostaining for TDP-43. The
overall percentage of spinal motor neurons with ubiquitin-positive
inclusions ranged from 3.17% to 57.14% (mean SD: 20.51
13.81) (Table 2).
After dividing the ALS cases into groups according to the mean
number of motor neurons counted in the anterior horns, the per-
centage of neurons showing ubiquitin-positive inclusions increased
with the decreasing number of neurons. This was not the case for
TDP-43. The highest percentage of neurons with diffuse cytoplas-
mic TDP-43 was counted in the anterior horns with the highest
number of residual neurons. Conversely, the percentage decreased
with the decreasing number of neurons, even if neurons with cyto-
plasmicTDP-43 were frequent also in the anterior horns containing
very fewmotor neurons (Figure 4). The percentage of neurons with
skein-like/round TDP-43 inclusions did not show a relevant modi-
fication with the decreasing number of neurons. The percentage of
TDP-43-positive skein/round inclusions was similar to that of the
ubiquitin-positive inclusions in the subgroups with more than 40
residual neurons. If the number of residual neurons was lower than
30, however, ubiquitin-positive inclusions were more numerous
than the TDP-43-positive ones (Table 1; Figure 4).
In the dentate gyrus of the hippocampus, neurons with cytoplas-
mic ubiquitin- and TDP-43-positive inclusions ranged from 1.69%
to 35.15%, and from 3.72% to 23.08%, respectively (Table 1). The
possibility that some TDP-43-positive cells be glial cells cannot be
excluded with certainty. Case by case, the percentage of ubiquitin-
immunopositive dentate neurons was similar to that of TDP-43-
positive ones, with the exception of case #7, an ALS-D patient
affected by long-lasting dementia, who had a higher percentage of
ubiquitin- than TDP-43-positive neurons (Figure 5).
Figure 1. Characterization of pellets A and B, and cytosolic fraction
from samples of amyotrophic lateral sclerosis spinal cord (ALS) and
controls (ctrl) by using the nuclear-specific markers lamin B1 and
histone H4. Pellets A and B are positive to the nuclear markers; the
cytosolic fraction [cytosolic fraction free from insoluble material (CS-F)]
is negative.
Giordana et al Cytosolic TDP-43 in ALS
353Brain Pathology 20 (2010) 351–360
© 2009 The Authors; Journal Compilation © 2009 International Society of Neuropathology
Figure 2. TDP-43 and ubiquitin
immunohistochemistry in sporadic ALS. (A)
TDP-43- and (B) ubiquitin-positive skein-like
inclusion in spinal motor neurons; the nuclei of
neurons are TDP-43-negative, DAB; (C), (D),
(E), (G), (H), (I) Diffuse cytoplasmic TDP-43
immunoreactivity in spinal motor neurons; (F)
no ubiquitin staining in the TDP-43-positive
neuron shown in (E), DAB; (J), (K)
TDP-43-positive cytoplasm of neurons in the
frontal cortex, DAB. Scale bars = 20 mm.
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Biochemistry
The characterization showed that pellets A and B were strongly
immunopositive to the two nuclear markers, while CS-F resulted to
be negative to the nuclear markers (Figure 1) and positive to the
cytosolic marker GAPDH (Figure 7). On this basis, CS-F resulted
to be free of nuclear components, while pellets A and B included
nuclear components in addition to the insoluble material. There-
fore, CS-F is representative of the soluble cytosolic compartment
and does not include nuclei and nuclear debris. The results of the
characterization prove that the storage of tissue specimens and the
procedures by which subcellular fractionation was carried out did
not cause any appreciable nuclear lysis. In addition, the absence of
pellet after high-speed centrifugation shows that CS-F is free from
insoluble bodies.
In the SarkI-P, derived from pellets A and B, the spectrum
of TDP-43 immunoreactivity in the blots from ALS spinal cord
(Figure 6A) reproduced the previously reported one (2, 29, 36),
highlighting a 43 kDa band accompanied by a 45 kDa band, a
28 kDa band and diffuse smeared staining including bands sized
well above 43. In the blots of control samples, the 43 kDa band only
was visible. These findings were reproduced in blots of SarkI-P
obtained from specimens of frontal cortex.
In CS-F fromALS spinal cord, the antibody toTDP-43 disclosed
two immunoreactive bands at 43 and 45 kDa, being the latter
darker than the former. By contrast, in the CS-F blots of controls,
the 43 kDa TDP-43 band was barely detectable and the 45 kDa
band was not visualized even after prolonged exposure to the anti-
body (Figure 7A). In both control andALS immunoblots, a variety
of TDP-43 immunoreactive bands sized around 38 kDa and below
were disclosed. A faint smear in the high-molecular mass range
was unveiled by the ubiquitin antibody in ALS and minimally in
controls (Figure 7B).
In the CS-F from frontal cortex specimens, aTDP-43 immunore-
active band at 43 kDa, accompanied by a 45 kDa band was an
exclusive feature of ALS cases (Figure 7C); a smear in the
high-molecular mass range was barely visible. A ubiquitin-
immunopositive wide smear localized well above 43 kDa was
present in CS-Fs from ALS and control specimens, being promi-
nent inALS (Figure 7D).
DISCUSSION
The novel finding of the present quantitative analysis is the preva-
lence of the diffuse cytoplasmic TDP-43 as compared to the round/
skein TDP-43 and ubiquitin immunoreactivity in ALS-affected
spinal motor neurons. The diffuse cytoplasmic staining found by us
in spinal motor neurons is reminiscent of theTDP-43 immunoposi-
tive fine granules diffusely scattered in the neuronal cytoplasm in a
number of brain areas of ALS patients (4, 27), in the hypoglossal
nucleus of ALS (11) and in lower motor neurons of familial ALS
with SOD1 gene mutation (32). Such immunostaining was consid-
ered as “pre-inclusions.” The progressive changes in the TDP-43
pathology going from diffuse/granular to skein/round inclusions
have been described (27, 33, 36).
The diffuse cytoplasm localization of TDP-43 in ALS motor
neurons revealed by immunohistochemistry is confirmed by our
biochemical analysis, highlighting a relevant 43 kDa TDP protein
band, accompanied by a 45 kDa band, in the cytosolic inclusion-
free fraction of ALS samples (CS-F). The banding pattern of CS-F
shares features with the pattern of the sarkosyl-insoluble fraction
reported in brain tissue fromALS and FTLD (2, 17, 23, 29, 36) and
Figure 3. Double-label immunofluorescence of cytoplasmic inclusions
in an anterior horn motor neuron of a sporadic amyotrophic lateral sclero-
sis patient: TDP-43 (A) and ubiquitin (B) do not completely overlap (C). A.
Ubiquitin: TRIC, red. B. TDP-43: FITC, green. C. Merged. ¥1000.
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reproduced by us. The 45 kDa band is considered to be the phos-
phorylated form of full-length TDP-43 (16, 29). The 28 kDa band
frequently reported in immunoblots fromALS (17, 29, 36) was not
evidenced in the CS-F; this is possibly caused by the difficulty
to detect these pathogenic C-terminal fragments with the anti-
TDP-43 antibody used. Consistently with the nuclear localization
of normal TDP-43, a 43 kDa band was not appreciable in the cyto-
solic fraction of control cortex and spinal cord, strengthening the
value of our results.
A significant finding is the poor correlation between the detec-
tion of cytosolic TDP-43 biochemically and the frequency of
immunohistochemical cytoplasmic TDP-43 reactivity in motor
cortex ofALS. The ability to detect changes biochemically in areas
without inclusions was reported for a-synuclein in multiple system
atrophy (10); it shows the existence of biochemically detected
occult pathology in neurodegenerative diseases.
A number of additional novel dysfunctions were disclosed by the
biochemical analysis. In the cytosolic fraction from ALS samples,
both full-length TDP-43 and the 45 kDa form are accumulated and
therefore independent of the inclusion bodies; these features were
not so far demonstrated. In addition, TDP-43 as a high-molecular
mass component tagged with various ubiquitin monomers is
present not only in the fraction containing the inclusion bodies, but
also in the cytosolic inclusion-free fraction. Therefore, ubiquiti-
nated TDP-43 results to be not only a component of the insoluble
inclusion bodies, but also a soluble cytosolic component in ALS.
Immunohistochemistry is not able to reveal the diffuse ubiquiti-
natedTDP-43.Additional bands below 38 kDa were visible in both
ALS and control blots; they have been considered to be proteolytic
products of TDP-43 (29).
TDP-43 is a highly conserved nuclear protein that acts as a
transcription repressor and activator of exon skipping (6), and is
involved in nuclear bodies (26). The redistribution of TDP-43 in
ALS may correspond to loss of nuclear function, resulting in tran-
scriptional deregulation, aberrant messenger RNA splicing and
disintegration of nuclear bodies. Reduced stabilization of mRNA
coding for the low-molecular weight isoform of neurofilaments
may also take place (36). Any of these defects can play a role in the
pathogenesis of ALS. Loss of TDP-43 nuclear function is consis-
tent with either abnormal subcellular distribution or abnormal
structural properties.
The events underlying the redistribution of TDP-43 in ALS
remain unclear. The abnormal accumulation of TDP-43 as a native
protein in the cytosolic fraction is, in itself, predictive of a defective
import–export process. The cause can be either impairment of the
transport mechanisms at the nuclear envelop or posttranslational
events that lead to anomalous/incorrect folding of the protein.
Either TDP-43 gene mutations or dysfunctions in the folding
machinery that interferes with correct trafficking across the nuclear
envelope can be responsible. In this respect, TDP-43 gene muta-
tions have recently been reported in sporadic and familialALS (13,
18, 35, 40, 42). Redistribution and sequestration of TDP-43 in
insoluble aggregates in neurons have been reproduced in cultured
cells by altering endogenous TDP-43 nuclear trafficking and by
expressing mutants with defective nuclear localization or nuclear
export signals (41).
The biochemical finding of TDP-43 in high-molecular mass
form and the correspondence of TDP-43 and ubiquitin bands in
parallel blots predict the existence of TDP-43 in an anomalous
structural conformation, because aberrant proteins are selective
substrates of ubiquitination (14, 19). In ALS, TDP-43 can be
viewed both as a structurally abnormal protein and an abnormal
cytosolic component, becoming a potential substrate for ubiquiti-
nation and/or segregation into insoluble aggregates.
Table 2. Percentage of TDP-43- and
ubiquitin-positive motor neurons in anterior
horns of 30 sporadic amyotrophic lateral
sclerosis patients.
Mean
number
(%)
Standard
deviation
(%)
Range (%)
Neurons with diffuse cytoplasmic TDP-43 31.11 27.93 0–88.89
Neurons with skein/round TDP-43 aggregates 12.17 11.08 0–37.50
Neurons with TDP-43 any type 43.27 23.91 8–94.83
Neurons with skein/round ubiquitin aggregates 20.51 13.81 3.17–57.14
Figure 4. Percentage of TDP-43- and
ubiquitin-positive spinal motor neurons by
number of residual motor neurons in anterior
horns of 30 sporadic amyotrophic lateral
sclerosis patients.
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The ubiquitin/proteasome system is implicated in the
processing of proteins and plays also a role in a large array of
functions essential for cellular homeostasis (14, 19, 31); there-
fore, ubiquitinated derivatives are normally found in control
tissues and cells by biochemical methods, as in the blots of our
control samples.
The progressive disappearance of motor neurons is the critical
event inALS. Evidence of different stages of the process, including
the presence of normal-appearing neurons is found in anterior
horns (5). Therefore, the number of surviving neurons in anterior
horns represents a surrogate marker of the stage of neurodegenera-
tion and disease progression. Survival duration of individual ALS
patients may not reflect the pathological stage, being survival influ-
enced by site of disease presentation, intercurrent morbid events
and supporting care in the advanced phases of illness. The trend of
the percentage of TDP-43-positive neurons by the absolute number
of surviving neurons in anterior horns, as well as the finding of
cytoplasmic TDP-43 accumulation in apparently healthy motor
neurons, suggests thatTDP-43 redistribution is an early event in the
pathogenic pathway leading to individual motor neuron death.
In addition, the present results suggest that the delocalization of
TDP-43 is an ongoing event during the disease progression, involv-
ing progressively intact neurons, and preceding the deposition of
insoluble inclusion bodies.
The trend of ubiquitin-positive andTDP-43-positive skein/round
inclusions indicates that the deposition of ubiquitinated bodies is a
late event. The association between the high percentage of ubiquiti-
nated neurons and the low number of residual neurons in anterior
horns, previously reported by us (34; see Figure 1), suggests that
ubiquitinated inclusions are the markers of the final stages of cell
damage. This interpretation is concordant with the reported signifi-
cant correlation between the presence of ubiquitin-immunoreactive
inclusions and absence of Nissl substance in anterior horn cells of
ALS patients (21).
The persistence of ubiquitinated inclusions as tombstones in
severely damaged motor neurons suggests an overloading of the
ubiquitin–proteasome system by an excess of altered proteins.
Abnormal accumulation of ubiquitinated derivatives is commonly
regarded as a hallmark of proteasome proteolytic function inhibi-
tion (1, 8). TDP-43 is probably a major protein undergoing ubiq-
uitination inALS; however, the identity of other abnormal proteins
remains unknown. The partial overlap between TDP-43 and ubiq-
uitin staining of neuronal inclusions in ALS was reported also by
others and considered as evidence that TDP-43 is not the unique
target of ubiquitination in ALS (33). Accumulation of ubiquitin-
tagged TDP-43 contributes to the hampering of proteasome-
mediated protein degradation.
In dentate neurons of the hippocampus, TDP-43 and ubiquitin
immunoreactivity do quantitatively overlap, with the exception of
one case with long-lasting dementia before ALS onset. In dentate
neurons, the abnormal compartmentalization ofTDP-43 is possibly
accompanied, or followed soon by ubiquitination. Ubiquitin-
positive inclusions are found in dentate neurons of 20%–60% of
sporadic ALS without a history of dementia (24), suggesting a
spectrum of FTD and ALS with a common underlying pathology.
In our series, dentate pathologywas found in 14% of non-demented
ALS patients and in the twoALS patients with dementia. A formal
neuropsychological evaluation of our ALS patients without frank
dementia could have revealed frontal type impairment in additional
ALS patients, as reported (22).
In conclusion, TDP-43 immunoreactivity in sporadic ALS
patients involves a larger number of spinal motor neurons than
ubiquitin and has two main features: (i) diffuse cytoplasmic stain-
ing; and (ii) skein/round inclusions. The altered distribution of
TDP-43 in the cytoplasm of the upper and lower motor neurons is
confirmed by our biochemical analysis, and is probably an early
event of the pathogenic pathway that leads to motor neuron degen-
eration. The coexistence of native TDP-43, hyperphosphorylated
TDP-43 and ubiquitinated TDP-43 in the cytosol suggests that
ubiquitination is a later event. Deleterious perturbation of nuclear
trafficking and/or solubility of TDP-43 may result in a loss of
function at the nuclear level, and/or in toxic gain of function in the
cytosolic compartment, both affecting neuron metabolic function
and vitality. The redistribution of TDP-43 seems to be an ongoing
event during disease progression. If this is the case, counteracting
this event may represent a rationale therapeutic approach to the
incurable disease.
Figure 5. Percentage of TDP-43- and ubiquitin- positive dentate
neurons of hippocampus in the six immunopositive amyotrophic lateral
sclerosis cases.
Figure 6. Immunoblotting of the sarkosyl-insoluble fraction (SarkI-P)
from spinal cord specimens of amyotrophic lateral sclerosis patients
(ALS) and control (ctrl) with antibodies to TDP-43 (A) and ubiquitin (B).
The 43 kDa band corresponds to full-length TDP-43; the 45 and 28 kDa
bands are pathological TDP-43 forms; the TDP-43-immunostained
protein bands below 43 kDa are presumably cleavage products of
TDP-43 (29). (*) High-molecular mass smear.
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